ribavirin pre-treatment — Competitive Intelligence Brief

ribavirin pre-treatment (ribavirin pre-treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antiviral. Area: Virology/Infectious Disease.

marketed Nucleoside analog antiviral Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism Virology/Infectious Disease Small molecule

Target snapshot

ribavirin pre-treatment (ribavirin pre-treatment) — University of Roma La Sapienza. Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and RNA-dependent RNA polymerase activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ribavirin pre-treatment TARGET	ribavirin pre-treatment	University of Roma La Sapienza	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism
Ribavirin (R)	Ribavirin (R)	Tibotec Pharmaceuticals, Ireland	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Ribavirin (Copegus®)	Ribavirin (Copegus®)	Vertex Pharmaceuticals Incorporated	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; inosine monophosphate dehydrogenase (IMPDH)
Valacyclovir (ZELITREX)	Valacyclovir (ZELITREX)	Assistance Publique - Hôpitaux de Paris	marketed	Nucleoside analog antiviral	Viral DNA polymerase (herpesvirus)
VAL	VAL	Estetra	marketed	Nucleoside analog antiviral	Cytomegalovirus (CMV) DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-09-22 — Lonsurf · RE46284 · US
• 2034-06-17 — Lonsurf · 10457666 · US
• 2034-06-17 — Lonsurf · 9527833 · US
• 2034-09-05 — Lonsurf · 9943537 · US
• 2037-02-03 — Lonsurf · 10456399 · US
• 2037-02-03 — Lonsurf · 10960004 · US

Sponsor landscape (Nucleoside analog antiviral class)

1. Merck Sharp & Dohme LLC · 3 drugs in this class
2. Hoffmann-La Roche · 2 drugs in this class
3. Göteborg University · 2 drugs in this class
4. Estetra · 1 drug in this class
5. Padagis LLC · 1 drug in this class
6. MinaPharm Pharmaceuticals · 1 drug in this class
7. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
8. NYU Langone Health · 1 drug in this class
9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
10. Ain Shams University · 1 drug in this class